CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Bioventus (BVS), Corvus Pharmaceuticals (CRVS) and Lifecore Biomedical (LFCR)
Press Release: Bioventus Completes Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners
Express News | Bioventus Completes Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners
Bioventus: Strategic Moves Amidst Financial Challenges Justify Hold Rating
J.P. Morgan Upgrades Bioventus(BVS.US) to Hold Rating, Raises Target Price to $13
Express News | Bioventus Inc : JP Morgan Raises to Neutral From Underweight; Raises Target Price to $13 From $12
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet
Earnings Call: Bioventus Reports Robust Q3 Growth, Raises Full-year Guidance
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Analyst Ratings
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $17
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $15
J.P. Morgan Maintains Bioventus(BVS.US) With Sell Rating, Announces Target Price $12
Bioventus (BVS) Gets a Sell From J.P. Morgan
Q3 2024 Bioventus Inc Earnings Call
Express News | Bioventus Inc : Canaccord Genuity Raises Target Price to $15 From $12
Bioventus Reports Strong Revenue Growth in Q3 2024
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings